BioCardia

Pre-Approval PRO BETA

Total Trials

Phase 3

Phase 2

Recruiting

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Heart Failure, Systolic ARDS, Human

NCT02438306 Phase 3 COMPLETED

CardiAMP™ Cell Therapy for Heart Failure Trial

Started: 12/1/2016

NCT05491681 Phase 1 WITHDRAWN

AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial

Started: 1/4/2026

NCT05925608 Phase 1 ACTIVE NOT RECRUITING

Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells

Started: 8/23/2023

intravenous delivery of allogeneic bone marrow-derived MSCs Autologous cell therapy

Activity Status: Active

Last Trial Started: 1/4/2026

Last Trial Ended: 6/1/2025

Trials (12 months): 1

Completed Trials: 1

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.